Cision PR Newswire

Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of...

XtraMaker Launches M1 Series on Kickstarter: The World’s First 5-in-1 Smart Desktop DTF Studio Built for Creators

SHENZHEN, China, Aug. 5, 2026 /PRNewswire/ -- Global DIY smart tool brand XtraMaker launched the M1 Series on Kickstarter at 9:00 AM PDT, August 4....

Guggenheim Abu Dhabi Appoints Inaugural Museum Director

ABU DHABI, UAE, Aug. 4, 2026 /PRNewswire/ -- The Department of Culture and Tourism – Abu Dhabi today announced the appointment of Dr. Valerie...

TECHTRONIC INDUSTRIES DELIVERS STRONG FIRST HALF PERFORMANCE

GROWING SALES TO US$8.3 BILLION, NET PROFIT INCREASED TO US$738 MILLION HONG KONG, Aug. 4, 2026 /PRNewswire/ -- Techtronic Industries Co. Ltd. ("TTI" or...